Insider trading

Period: 120 months Stock: FATE Plan: Not stated × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

136 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

136 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

136 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

136 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
136 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
136 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

136 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
13 Jan 2023
MENDLEIN JOHN Director
Bought
$198.91K 36,631 at 5.43
14.9%
11 Jan 2023
MENDLEIN JOHN Director
Bought
$499.23K 88,048 at 5.67
55.7%
First buy on file
10 Jan 2023
Wolchko J Scott President and CEO
Sold, plan not stated
$240.55K 45,907 at 5.24
10.6%
10 Jan 2023
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$60.54K 11,553 at 5.24
6.1%
10 Jan 2023
Valamehr Bahram Chief R&D Officer
Sold, plan not stated
$57.21K 10,917 at 5.24
6.1%
10 Jan 2023
Chu Yu-Waye Chief Medical Officer
Sold, plan not stated
$41.00K 7,825 at 5.24
5.2%
10 Jan 2023
Dulac Edward J III Chief Financial Officer
Sold, plan not stated
$38.41K 7,331 at 5.24
5.4%
10 Jan 2023
Plavsic Mark Chief Technical Officer
Sold, plan not stated
$17.91K 3,418 at 5.24
2.7%
18 Aug 2022
Dulac Edward J III Chief Financial Officer
Sold, plan not stated 2×
$153.05K 5,135 at 29.81
3.6%
22 Jul 2022
Wolchko J Scott President and CEO
Sold, plan not stated 3×
$200.36K 6,246 at 32.08
1.4%
21 Jul 2022
Wolchko J Scott President and CEO
Sold, plan not stated 2×
$986.36K 30,000 at 32.88
6.5%
7 Jul 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated
$518.69K 17,158 at 30.23
8.7%
6 Jul 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated
$235.81K 7,842 at 30.07
4.2%
5 Jul 2022
Plavsic Mark Chief Technical Officer
Sold, plan not stated
$91.52K 3,719 at 24.61
2.8%
7 Jun 2022
Agarwal Shefali Director
Sold, plan not stated
$18.41K 841 at 21.89
31.4%
3 Jun 2022
Jooss Karin Director
Sold, plan not stated
$33.84K 1,483 at 22.82
55.3%
Sold half or more
3 Jun 2022
Coughlin Timothy Director
Sold, plan not stated
$32.82K 1,439 at 22.81
2.4%
3 Jun 2022
MENDLEIN JOHN Director
Sold, plan not stated
$31.09K 1,364 at 22.79
0.9%
3 Jun 2022
Agarwal Shefali Director
Sold, plan not stated
$18.40K 807 at 22.80
30.1%
3 Jun 2022
HERSHBERG ROBERT Director
Sold, plan not stated
$15.29K 672 at 22.75
25.1%
1 Jun 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$574.00K 25,000 at 22.96
11.7%
22 Apr 2022
Wolchko J Scott President and CEO
Sold, plan not stated 2×
$345.91K 10,000 at 34.59
2.3%
21 Apr 2022
Wolchko J Scott President and CEO
Sold, plan not stated 4×
$1.05M 30,000 at 35.00
6.5%
19 Apr 2022
Chu Yu-Waye Chief Medical Officer
Sold, plan not stated
$143.67K 4,062 at 35.37
2.6%
1 Apr 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$971.25K 25,000 at 38.85
11.7%
14 Mar 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 5×
$776.73K 25,000 at 31.07
12.2%
10 Mar 2022
MENDLEIN JOHN Director
Sold, plan not stated 2×
$1.11M 31,562 at 35.02
16.5%
21 Jan 2022
Wolchko J Scott President and CEO
Sold, plan not stated
$380.20K 10,000 at 38.02
2.3%
20 Jan 2022
Wolchko J Scott President and CEO
Sold, plan not stated
$1.21M 30,000 at 40.21
6.5%
11 Jan 2022
Wolchko J Scott President and CEO
Sold, plan not stated 2×
$709.03K 14,566 at 48.68
3.3%
11 Jan 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 2×
$262.97K 5,419 at 48.53
3.4%
11 Jan 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 2×
$221.66K 4,570 at 48.50
3.0%
11 Jan 2022
Chu Yu-Waye Senior VP Clinical Development
Sold, plan not stated 2×
$192.34K 3,965 at 48.51
3.2%
11 Jan 2022
Dulac Edward J III Chief Financial Officer
Sold, plan not stated 2×
$85.76K 1,770 at 48.45
1.6%
10 Jan 2022
Wolchko J Scott President and CEO
Sold, plan not stated 3×
$1.60M 34,156 at 46.86
7.1%
10 Jan 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 2×
$359.31K 7,738 at 46.43
4.6%
10 Jan 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 2×
$259.56K 5,596 at 46.38
3.6%
3 Jan 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 4×
$2.97M 50,000 at 59.34
22.8%
20 Dec 2021
Dulac Edward J III Chief Financial Officer
Sold, plan not stated
$958.62K 15,977 at 60.00
12.6%
13 Dec 2021
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 5×
$1.19M 25,000 at 47.66
13.8%
10 Dec 2021
Chu Yu-Waye Senior VP Clinical Development
Sold, plan not stated 7×
$385.95K 7,500 at 51.46
5.6%
18 Nov 2021
Wolchko J Scott President and CEO
Sold, plan not stated
$1.09M 20,000 at 54.27
4.8%
22 Oct 2021
Wolchko J Scott President and CEO
Sold, plan not stated
$1.77M 30,000 at 58.88
7.1%
21 Oct 2021
Wolchko J Scott President and CEO
Sold, plan not stated 2×
$1.81M 30,000 at 60.22
7.1%
1 Oct 2021
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 3×
$2.94M 50,000 at 58.83
31.6%
28 Sep 2021
Dulac Edward J III Chief Financial Officer
Sold, plan not stated
$1.22M 19,460 at 62.53
27.1%
13 Sep 2021
Valamehr Bahram Chief Development Officer
Sold, plan not stated 3×
$1.66M 25,000 at 66.29
20.7%
19 Aug 2021
Wolchko J Scott President and CEO
Sold, plan not stated
$1.76M 20,000 at 88.01
4.8%
19 Aug 2021
Dulac Edward J III Chief Financial Officer
Sold, plan not stated 3×
$306.60K 3,474 at 88.26
6.0%
23 Jul 2021
Wolchko J Scott President and CEO
Sold, plan not stated
$2.56M 30,000 at 85.28
7.1%
Showing 1–50 of 136. Page 1 of 3 Older →